Dr Firas Abdollah,Henry Ford Health,United States
Dr. Firas Abdollah is a Clinical Associate Professor and Vice-Chair of Academic and Research at the Vattikuti Urology Institute, Henry Ford Hospital. With dual citizenship in the USA and Italy, he has a distinguished career in urologic oncology and robotic surgery. He specializes in the epidemiology of urologic cancers and the development of predictive tools for cancer outcomes. He has held research and faculty positions at leading institutions, including Wayne State University and Michigan State University. His extensive contributions to urology have earned him numerous awards, and his research has been published in top-tier journals. Dr. Abdollah is also a medical consultant for Intuitive Surgical Inc.
Publication Profile
Orcid
Education
Dr Firas Abdollah began his academic journey at Al Mutamayizeen Secondary School in Baghdad, Iraq, where he completed his Bachelor of Science between 1995 and 1997. He then pursued a Doctor of Medicine degree at the College of Medicine, Baghdad University, graduating in 2003. Following his medical education, he underwent extensive training through internships and residency at San-Raffaele Hospital, University Vita-Salute, in Milan, Italy, from 2004 to 2012. Further advancing his expertise, he completed a prestigious Fellowship in Robotic Urologic Oncology at the Henry Ford Hospital, Vattikuti Urology Institute, in Detroit, Michigan, USA, from 2015 to 2018.
Experience
Associate Professor at Wayne State University, a position he has held since 2020, and also serves as Vice-Chair of Academic and Research at the Vattikuti Urology Institute, Henry Ford Hospital. In addition, he has been a Clinical Associate Professor at Michigan State University since 2022. His extensive experience in medical consulting includes his current role at Intuitive Surgical Inc., California, starting in 2024. Previously, he was a Medical Consultant for the Department of Urology at the Academic Hospital San Raffaele in Milan, Italy, from 2011 to 2013, and served as a Medical Consultant and Advisor for GenomeDx Biosciences in Vancouver, Canada, from 2014 to 2020. His collaboration with KOELIS Inc. in Delaware lasted from 2022 to 2024 through a consulting and research agreement. Dr. [Name] has also been actively involved in research, having worked as a Research Investigator at Henry Ford Hospital, focusing on prognostic models for prostate and bladder cancers from 2014 to 2015. Earlier in his career, he contributed to cancer prognostics and health outcomes research at the University of Montreal in 2010.
Awards & Honors
- Best Poster Award – Società Italiana di Urologia Annual Congress (2007)
- Best of AUA/JUA Meeting Award – AUA Annual Meeting, Washington DC (2011)
- Best Paper – European Urology Resident Corner (2012)
- Best Poster Award – European Association of Urology Congress (2012, 2013, 2014, 2018)
- Excellence in Research Award – Southeast Michigan Center for Medical Education (2017)
- Top 1% in Field for Peer Reviews – Publons (2017)
- First Place, Fellow Clinical Research – European Association of Urology Congress (2018)
Research Focus
- Epidemiology of Urologic-Oncology Diseases
- Prostate, Kidney, Bladder, Testicular, and Penile Cancers
- Development of Prediction Tools for Disease-Specific Mortality and Recurrence
- Robotic Urologic Oncology and Outcomes Resear
Publication
- 📖 The importance of pelvic lymph node dissection in the elderly: Implications for interpretation of NCCN guidelines
- 📖 A novel tool for predicting urinary incontinence after radical prostatectomy
- 📖 Competing risks analysis of long-term survival in node-positive prostate cancer
- 📖 Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy
- 📖 Testing the impact of adjuvant radiotherapy on overall mortality in prostate cancer patients
- 📖 External validity of EORTC 30904 in North American patients with renal cell carcinoma